Murex HCV Ag/Ab combination
Enzyme immunoassay designed to detect reactive HIV core antigen
Assay Principle:
Ag and Ab sandwich 4th generation ELISA
• Improved throughput by simultaneous detection of HCV antigen and antibody in a single assay run.
• High security for the operator with dispense monitoring for all steps.
• Ease of use by performing the Murex HCV Ag/Ab combination assay in manual, semi-automated or fully automated way.
• Significant reduction of the windows period by using HCV combination assays by at least 26 days compared to anti-HCV assays.
• More blood safety by earlier detection of HCV infection (average 20.57 days earlier than in the antibody only assays, assessed on 30 commercial seroconversion panels)
• High security for the operator with dispense monitoring for all steps.
• Ease of use by performing the Murex HCV Ag/Ab combination assay in manual, semi-automated or fully automated way.
• Significant reduction of the windows period by using HCV combination assays by at least 26 days compared to anti-HCV assays.
• More blood safety by earlier detection of HCV infection (average 20.57 days earlier than in the antibody only assays, assessed on 30 commercial seroconversion panels)
